EBOVAC2 in numbers

  • 6 Organisations: 4 institutes, 1 Industrial partner, 1 private company in charge of Management
  • 3 European Union member states involved
  • Budget: €22,790,820 (IMI JU funding); EFPIA contribution: €15.1 million
  • 3 year-duration: 1st December 2014 – 30 November 2017

News

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018

  • 02 January 2018

    The 4th edition of our EBOVAC2 newlsetter was released on the 21st of December 2017.

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research